We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
NovAliX Enters into Multi-Target Integrated Drug Discovery Collaboration with Teijin Pharma
News

NovAliX Enters into Multi-Target Integrated Drug Discovery Collaboration with Teijin Pharma

NovAliX Enters into Multi-Target Integrated Drug Discovery Collaboration with Teijin Pharma
News

NovAliX Enters into Multi-Target Integrated Drug Discovery Collaboration with Teijin Pharma

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "NovAliX Enters into Multi-Target Integrated Drug Discovery Collaboration with Teijin Pharma"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

NovAliX will initially use its protein biochemistry expertise in combination with its comprehensive biophysical technology platform. NovAliX will apply its proprietary Graffinity SPR-based screening technology for the identification of novel chemotypes, and then engage its native nano-MS technology for further characterization of selected small molecule hit structures.

This arrangement represents NovAliX’ first discovery collaboration with Teijin Pharma. Under the terms of the agreement NovAliX will receive technology access fees as well as further research funding payments. Financial details of the transaction were not disclosed.

Stephan Jenn, President of NovAliX, stated, ”We are confident that this alliance will be very productive and are proud to be associated with Teijin’s technology-driven team. In this collaboration Teijin will have the opportunity to leverage the entire spectrum of our capabilities in biochemistry, biophysics and medicinal chemistry. For NovAliX this integrated collaboration represents a significant milestone as Teijin is the second Japanese pharmaceutical company to partner with us this year. This alliance underlines again the competitive edge of our scientific expertise and biophysical technologies as well as our commitment to serve the Japanese pharmaceutical research market that is strongly driven by science and innovation.”

Advertisement